RhumbLine Advisers’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-79,568
| Closed | -$1.2M | – | 3064 |
|
|
2022
Q3 | $1.2M | Buy |
79,568
+12,099
| +18% | +$141K | ﹤0.01% | 2040 |
|
|
2022
Q2 | $506K | Buy |
67,469
+17,886
| +36% | +$126K | ﹤0.01% | 2497 |
|
|
2022
Q1 | $451K | Buy |
49,583
+1,157
| +2% | +$8.92K | ﹤0.01% | 2468 |
|
|
2021
Q4 | $340K | Buy |
48,426
+493
| +1% | +$5.16K | ﹤0.01% | 2671 |
|
|
2021
Q3 | $546K | Buy |
47,933
+2,053
| +4% | +$30K | ﹤0.01% | 2505 |
|
|
2021
Q2 | $735K | Sell |
45,880
-302
| -0.7% | -$5.18K | ﹤0.01% | 2385 |
|
|
2021
Q1 | $825K | Sell |
46,182
-4,668
| -9% | -$80.6K | ﹤0.01% | 2279 |
|
|
2020
Q4 | $687K | Buy |
50,850
+1,346
| +3% | +$16.3K | ﹤0.01% | 2308 |
|
|
2020
Q3 | $583K | Sell |
49,504
-13,847
| -22% | -$169K | ﹤0.01% | 2217 |
|
|
2020
Q2 | $935K | Buy |
63,351
+3,593
| +6% | +$53.2K | ﹤0.01% | 2075 |
|
|
2020
Q1 | $807K | Sell |
59,758
-850
| -1% | -$16.1K | ﹤0.01% | 1978 |
|
|
2019
Q4 | $1.47M | Buy |
60,608
+2,374
| +4% | +$49.2K | ﹤0.01% | 1914 |
|
|
2019
Q3 | $1.12M | Buy |
58,234
+663
| +1% | +$15.2K | ﹤0.01% | 1988 |
|
|
2019
Q2 | $1.7M | Buy |
57,571
+10,460
| +22% | +$403K | ﹤0.01% | 1836 |
|
|
2019
Q1 | $2.24M | Sell |
47,111
-357
| -0.8% | -$15.7K | ﹤0.01% | 1649 |
|
|
2018
Q4 | $1.71M | Buy |
47,468
+15,074
| +47% | +$707K | ﹤0.01% | 1736 |
|
|
2018
Q3 | $1.99M | Sell |
32,394
-2,225
| -6% | -$143K | ﹤0.01% | 1663 |
|
|
2018
Q2 | $2.34M | Buy |
34,619
+2,827
| +9% | +$158K | ﹤0.01% | 1591 |
|
|
2018
Q1 | $1.73M | Sell |
31,792
-42
| -0.1% | -$2.35K | ﹤0.01% | 1693 |
|
|
2017
Q4 | $1.9M | Sell |
31,834
-4,811
| -13% | -$292K | ﹤0.01% | 1649 |
|
|
2017
Q3 | $1.78M | Buy |
36,645
+1,732
| +5% | +$94.5K | ﹤0.01% | 1679 |
|
|
2017
Q2 | $1.83M | Buy |
34,913
+1,237
| +4% | +$57.6K | ﹤0.01% | 1630 |
|
|
2017
Q1 | $1.53M | Buy |
33,676
+3,816
| +13% | +$170K | ﹤0.01% | 1704 |
|
|
2016
Q4 | $1.13M | Buy |
29,860
+5,838
| +24% | +$221K | ﹤0.01% | 1788 |
|
|
2016
Q3 | $907K | Buy |
24,022
+1,062
| +5% | +$23.4K | ﹤0.01% | 1865 |
|
|
2016
Q2 | $404K | Buy |
22,960
+1,975
| +9% | +$32K | ﹤0.01% | 2341 |
|
|
2016
Q1 | $255K | Buy |
20,985
+1,325
| +7% | +$21K | ﹤0.01% | 2613 |
|
|
2015
Q4 | $479K | Buy |
19,660
+2,200
| +13% | +$51.3K | ﹤0.01% | 2261 |
|
|
2015
Q3 | $310K | Buy |
17,460
+685
| +4% | +$12.4K | ﹤0.01% | 2515 |
|
|
2015
Q2 | $296K | Buy |
16,775
+7,455
| +80% | +$137K | ﹤0.01% | 2668 |
|
|
2015
Q1 | $292K | Buy |
9,320
+1,300
| +16% | +$37.7K | ﹤0.01% | 2635 |
|
|
2014
Q4 | $234K | Buy |
+8,020
| New | +$203K | ﹤0.01% | 2713 |
|
RhumbLine Advisers's AERI Position: Q4 2022 in Review
RhumbLine Advisers sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 79,568 shares — an estimated $1.2M sold.
RhumbLine Advisers first reported a position in AERI in Q4 2014 and held it in 32 quarters. The position peaked at $2.34M in Q2 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- RhumbLine Advisers reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- RhumbLine Advisers sold 79,568 Aerie Pharmaceuticals shares in Q4 2022, an estimated $1.2M.
- RhumbLine Advisers first reported a position in Aerie Pharmaceuticals in Q4 2014 and held it in 32 quarters.
- RhumbLine Advisers's Aerie Pharmaceuticals position peaked at $2.34M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on RhumbLine Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.